| Identification | |
| Name: | ORTHO-HYDROXY ATORVASTATIN |
| Synonyms: | ORTHO-HYDROXY ATORVASTATIN;(R,dR)-2-(4-fluorophenyl)-,d-dihydroxy-4-[[(2-hydroxyphenyl)amino]carbonyl]-5-(1-methylethyl)-3-phenyl-1H-pyrrole-1-heptanoic Acid Dihydrate Monosodium Salt;BMS 243887-01;PD 152873;(R,dR)-2-(4-fluorophenyl)-,d-dihydroxy-4-[[(2-hydroxyphenyl)amino]carbonyl]-5-(1-methylethyl)-3-(phenyl-d5)-1H-pyrrole-1-heptanoic Acid Disodium Salt;o-Hydroxyatorvastatin Disodium Salt;2-Hydroxy Atorvastatin Dihydrate Monosodium Salt |
| CAS: | 214217-86-4 |
| Molecular Formula: | C33H34FN2O6.Na.2H2O |
| Molecular Weight: | 632.657 |
| Molecular Structure: | ![(C33H34FN2O6.Na.2H2O) ORTHO-HYDROXY ATORVASTATIN;(R,dR)-2-(4-fluorophenyl)-,d-dihydroxy-4-[[(2-hydroxyphenyl)amino]carbony...](https://img.guidechem.com/structure/214217-86-4.gif) |
| Properties | |
| Usage: | A metabolite of Atorvastin, a selective, competitive HMG-CoA reductase inhibitor. Atorvastin is the only drug in its class specfically indicated for lowering both elevated LDL-cholesterol and triglycerides in patients with hypercholesterolemia |
| Safety Data | |
 |
|
